Companies › Somagenetix
1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SGX-001 Autologous CD34+ HSPCs transduced with lentiviral vector encoding human NCF1 gene | – | Phase 1 | Chronic Granulomatous Disease (CGD) | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07826767 | SGX-001 | Phase 1 | Chronic Granulomatous Disease (CGD) | Hematology | Jul 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.